

**Amendments to the Claims:**

*This listing of claims will replace all prior versions, and listings, of claims in the application:*

1. (Original) Combinations of an antiemetic agent with an enkephalinase inhibitor.
2. (Original) The combination according to claim 1, wherein said antiemetic is a 5-HT<sub>3</sub> receptor antagonist.
3. (Original) The combination according to claim 2, wherein said 5-HT<sub>3</sub> receptor antagonist is selected from the group consisting of ondansetron and granisetron.
4. (Previously Presented) The combination according to claim 1 wherein said enkephalinase inhibitor is selected from the group consisting of racecadotril and dexecadotril.
5. (Previously Presented) A pharmaceutical composition comprising the combination according to claim 1, and a pharmaceutically acceptable vehicle or excipient.
6. (Currently Amended) The ~~pharmaceutical composition~~ combination according to claim ~~5~~ 1, wherein said ~~pharmaceutical composition~~ combination is for simultaneous, separate or sequential administration of said enkephalinase inhibitor and said antiemetic agent.
7. (Previously Presented) The pharmaceutical composition according to claim 5, wherein said pharmaceutical composition is suitable for oral administration.

8. (Previously Presented) The pharmaceutical composition according to claim 5, wherein said pharmaceutical composition is in the form of tablets, capsules or granulated powder.

9. (Previously Presented) The pharmaceutical composition according to claim 5, wherein said pharmaceutical composition of the invention comprises between 50 and 100 mg of said enkephalinase inhibitor per dosage unit for adults and corresponding doses according to body weight for children and babies.

10. (Previously Presented) The pharmaceutical composition according to claim 5 wherein said pharmaceutical composition comprises between 1 and 8 mg of a 5-HT<sub>3</sub> antagonist per dosage unit for adults and corresponding doses according to body weight for children and babies.

11. (Previously Presented) The pharmaceutical according to claim 5 wherein said pharmaceutical composition comprises between 2 and 8 mg of ondansetron per dosage unit for adults and corresponding doses according to body weight for children and babies.

12. (Previously Presented) The pharmaceutical composition according to claim 5, wherein said pharmaceutical composition comprises between 1 and 4 mg of granisetron per dosage unit for adults and corresponding doses according to body weight for children and babies.

13. (Currently Amended) The pharmaceutical composition according to claim 5, wherein said ~~pharmaceutical composition comprises the combination~~ comprises the antiemetic agent and the enkephalinase inhibitor of the invention in the same dosage unit.

14. (Currently Amended) ~~Use of the A method for the treatment of acute gastroenteritis,~~ comprising administering a combination of an antiemetic agent with an enkephalinase

~~inhibitor in the preparation of a pharmaceutical composition according to claim 5 for the treatment of acute gastroenteritis.~~

15. (Currently Amended) ~~Use of the~~ A method for the treatment of acute diarrhea associated with emesis, comprising administering a combination of an antiemetic agent with an enkephalinase inhibitor ~~in the preparation of a pharmaceutical composition according to claim 5 for the treatment of acute diarrhea associated with emesis.~~

16. (Currently Amended) ~~Use~~ The method according to claim 15, wherein said ~~diarrhoea~~ diarrhea is chemotherapy-induced diarrhea, carcinoid diarrhea, traveller's diarrhea, diarrhea elicited by various bacteria, viruses or parasites.

17. (Currently Amended) ~~Use~~ The method according to claim 14, wherein said treatment comprises oral administration, preferably two to four times a day.

18. (Currently Amended) ~~Use~~ The method according to claim 14, comprising administering the combination of an antiemetic agent with an enkephalinase inhibitor in ~~the preparation of a pharmaceutical composition, wherein said treatment comprises administration of the composition according to claim 5 two to four times a day.~~

19. (Currently Amended) ~~Use~~ The method according to claim 14, wherein said combination comprises dexcedotril and ondansetron ~~for the preparation of a pharmaceutical composition for the treatment of acute gastroenteritis by simultaneous, separate or sequential oral administration of the active ingredients.~~